In June of this year, the vaccine jointly developed by Oxford University and AstraZeneca started a Phase III clinical trial in Brazil. Up to now, 8,000 volunteers in Brazil have participated in the study.
Brazil’s “Globe” reported on the 21st that a Brazilian volunteer who participated in the Oxford University new crown virus vaccine trial died. The Brazilian National Health Supervision Agency (Anvisa) said that the agency officially learned of this information on the 19th, and the authenticity of the information has been confirmed.
According to the “Globe”, the volunteer who died was a 28-year-old male doctor who had been working in a hospital in Rio since March this year and was fighting on the front line of the epidemic. It is reported that the volunteer was in good health before. In late July, he was vaccinated with a vaccine jointly developed by Oxford University and AstraZeneca. He was infected with the new crown virus in September this year and died of new crown pneumonia and complications on the 15th of this month.
Brazilian news website “G1” stated that Anvisa did not disclose whether the volunteer was vaccinated or a placebo. The agency said that in accordance with the ethical confidentiality commitment, relevant data will not be disclosed. Anvisa said that the agency will persist in fulfilling its mission of protecting the health of Brazilians and recommends continuing research on Oxford vaccines.
In June of this year, the vaccine jointly developed by Oxford University and AstraZeneca started a Phase III clinical trial in Brazil. Up to now, 8,000 volunteers in Brazil have participated in the study. Earlier, Brazilian President Bolsonaro signed an interim measure allowing the federal government to allocate 1.9 billion reais (about 2.2 billion yuan) to purchase 100 million doses of Oxford vaccine.
